Latest News
GoldON Resources (GLD.V) is a low downside, crazy upside play on the back of Great Bear and West Red Lake
Top 5 Gainers and Losers: CUU.V, BSR.V, XYBN.V
ALSET Capital (KSUM.V) is the picks and shovels play for NVIDIA H100 AI GPUs
Skyharbour Resources (SYH.V) partner reports uranium mineralization
FansUnite (FANS.TO) reports Q1 2024 financial results
Top 5 Gainers and Losers: AMC.TO, FT.TO, DEF.V
Medexus Pharmaceuticals (MDP.T) – First Glance with Jody Vance E102
In today’s episode, Jody speaks with Ken d’Entremont, CEO & director of Medexus Pharmaceuticals, a Canadian-based company focused on improving and fast-tracking already-approved specialty drugs into the Canadian and American markets.
Enjoy!
Related Posts
Potential of Medexus Pharmaceuticals: Chris Parry gets into what investors are missing
Medexus Pharma (MDP.TO) Breaks Records: A Deep Dive into Quarterly Earnings, Portfolio Growth, and Future Opportunities
Medexus Pharmaceuticals (MDP): A Roller Coaster Ride to Success
Medexus Pharmaceuticals Sets New Revenue Records and Continues Expansion with Innovative Products and Financing
Medexus Pharmaceuticals (MDP.T) deals with its debentures
Medexus CEO (MDP.T) on creating Canada’s specialty pharma success story
More on MDP.T
Potential of Medexus Pharmaceuticals: Chris Parry gets into what investors are missing
Medexus Pharma (MDP.TO) Breaks Records: A Deep Dive into Quarterly Earnings, Portfolio Growth, and Future Opportunities
Medexus Pharmaceuticals (MDP): A Roller Coaster Ride to Success
Medexus Pharmaceuticals Sets New Revenue Records and Continues Expansion with Innovative Products and Financing
Medexus Pharmaceuticals (MDP.T) deals with its debentures
Medexus CEO (MDP.T) on creating Canada’s specialty pharma success story